找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Small Molecules in Oncology; Uwe M. Martens Book 2014Latest edition Springer-Verlag Berlin Heidelberg 2014 Molecular mechanisms of cancer.

[复制链接]
查看: 7934|回复: 64
发表于 2025-3-21 18:09:24 | 显示全部楼层 |阅读模式
书目名称Small Molecules in Oncology
编辑Uwe M. Martens
视频video
概述Detailed coverage of the most recent developments in targeted cancer therapy using small molecules.Full discussion of preclinical studies, clinical trials, and treatment applications.Written by acknow
丛书名称Recent Results in Cancer Research
图书封面Titlebook: Small Molecules in Oncology;  Uwe M. Martens Book 2014Latest edition Springer-Verlag Berlin Heidelberg 2014 Molecular mechanisms of cancer.
描述Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
出版日期Book 2014Latest edition
关键词Molecular mechanisms of cancer; Oncogenic protein kinase inhibitors; Targeted therapy; Treatment of mal
版次2
doihttps://doi.org/10.1007/978-3-642-54490-3
isbn_softcover978-3-662-51925-7
isbn_ebook978-3-642-54490-3Series ISSN 0080-0015 Series E-ISSN 2197-6767
issn_series 0080-0015
copyrightSpringer-Verlag Berlin Heidelberg 2014
The information of publication is updating

书目名称Small Molecules in Oncology影响因子(影响力)




书目名称Small Molecules in Oncology影响因子(影响力)学科排名




书目名称Small Molecules in Oncology网络公开度




书目名称Small Molecules in Oncology网络公开度学科排名




书目名称Small Molecules in Oncology被引频次




书目名称Small Molecules in Oncology被引频次学科排名




书目名称Small Molecules in Oncology年度引用




书目名称Small Molecules in Oncology年度引用学科排名




书目名称Small Molecules in Oncology读者反馈




书目名称Small Molecules in Oncology读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

1票 100.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:06:32 | 显示全部楼层
发表于 2025-3-22 00:33:01 | 显示全部楼层
发表于 2025-3-22 06:24:42 | 显示全部楼层
发表于 2025-3-22 09:49:23 | 显示全部楼层
Regorafenib,tatic gastrointestinal stromal tumors (GIST) after progression on standard treatments and is also an FDA approved indication. Currently, regorafenib is examined in several clinical trials (mostly phase II) in different tumor entities, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and soft tissue sarcoma (STS).
发表于 2025-3-22 14:38:26 | 显示全部楼层
发表于 2025-3-22 20:08:18 | 显示全部楼层
发表于 2025-3-23 00:59:34 | 显示全部楼层
发表于 2025-3-23 01:57:55 | 显示全部楼层
发表于 2025-3-23 09:32:40 | 显示全部楼层
Ruxolitinib,olitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors. Several further JAK inhibitors are currently studied in myelofibrosis or other immuno-inflammatory diseases.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-20 06:43
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表